Eotaxin but not MCP-3 induces eosinophil influx into nasal fluid in allergic patients.
BACKGROUND
Eotaxin and MCP-3 (CC chemokines), owing to their preferential action on eosinophils, seem to be the very importance in the patophysiology of allergic rhinitis and asthma. The purpose of this study was to examine the effect of intranasally administered eotaxin and MCP-3 after specific allergen priming on the influx of inflammatory cells and their soluble mediators into the nasal mucosa.


METHODS
Eotaxin and MCP-3 have been applied intranasally at the increasing doses of 1, 5 and 10 microg to allergic patients after allergen priming. The 'nasal pool' technique was used. The cell count and biochemical parameters in nasal lavage were evaluated before 30 min, and 4 and 24 h after the challenge with chemokines.


RESULTS
Both eotaxin and MCP-3 induced the increase in clinical 'score' lasting till 24 h. Eosinophil influx into nasal mucosa after provocation with eotaxin was also observed. The challenge with MCP-3 did not induce any significant changes in nasal lavage fluid.


CONCLUSIONS
Eotaxin is likely to play an important role in the pathogenesis of allergic conditions in humans. MCP-3 did not induce inflammatory cell influx into nasal mucosa. The role of this chemokine in the pathogenesis of allergic inflammation is difficult to assess and requires further studies.
Górski
P
P
Department of Occupational Medicine, Center of Occupational and Environmental Allergy, The Nofer Institute of Occupational Medicine, Lodz, Poland.
Wittczak
T
T
Walusiak
J
J
Pałczyński
C
C
Ruta
U
U
Kuna
P
P
Alam
R
R
D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects; D001491:Basophils / Q000187:drug effects / Q000378:metabolism; D001798:Blood Proteins / Q000187:drug effects / Q000378:metabolism; D054413:Chemokine CCL11; D054410:Chemokine CCL7; D019742:Chemokines, CC / Q000008:administration & dosage* / Q000009:adverse effects* / Q000493:pharmacokinetics; D016207:Cytokines; D004306:Dose-Response Relationship, Immunologic; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000097:blood / Q000209:etiology*; D018836:Inflammation Mediators / Q000378:metabolism; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D018945:Monocyte Chemoattractant Proteins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000493:pharmacokinetics; D009297:Nasal Mucosa / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D009299:Nasal Provocation Tests; D010539:Permeability / Q000187:drug effects; D011044:Poland; D012260:Ribonucleases; D012697:Serine Endopeptidases / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D053802:Tryptases
D000485:Allergens; D001798:Blood Proteins; C515456:CCL11 protein, human; C515450:CCL7 protein, human; D054413:Chemokine CCL11; D054410:Chemokine CCL7; D019742:Chemokines, CC; D016207:Cytokines; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D018945:Monocyte Chemoattractant Proteins; D012260:Ribonucleases; D012697:Serine Endopeptidases; D053802:Tryptases